Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott hopes to have first FDA-cleared NGAL test for kidney injury

This article was originally published in Clinica

Executive Summary

Abbott has filed a 510(k) application with the US FDA for a urine test to identify patients at risk of developing acute kidney injury (AKI). If approved, it will be the first diagnostic available in the US to measure the biomarker neutrophil gelatinase-associated lipocalin (NGAL), the company claims. The test is already CE marked for sale in Europe. Inverness Medical Innovations is also developing an NGAL test, which is available in Europe but not the US. Inverness' product analyses blood rather than urine, but both tests can diagnose AKI earlier in the disease process than the current gold standard, serum creatinine.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel